Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Zoetis Inc.

Navigating SG&A Expenses: A Tale of Two Giants

In the competitive landscape of pharmaceuticals, effective cost management is crucial. Over the past decade, Merck & Co., Inc. and Zoetis Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have fluctuated, peaking in 2014 and 2019, with a notable dip in 2020. This reflects a strategic shift, possibly due to market conditions or internal restructuring. In contrast, Zoetis has shown a steady increase, with expenses rising by approximately 31% from 2014 to 2023. This growth could indicate an aggressive expansion strategy or increased investment in marketing and sales. Understanding these trends provides valuable insights into how these companies navigate financial challenges and opportunities in a dynamic market.